• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Genoa raises $62m Series A for inhaled lung drug

May 15, 2017 By Sarah Faulkner

LungGenoa Pharmaceuticals said today that it raised $62 million in a Series A round to support the development of inhaled therapies for idiopathic pulmonary fibrosis and other severe pulmonary conditions. The round was led by F-Prime Capital Partners and Edmond de Rothschild Investment Partners.

Novo AS, RiverVest Venture Partners and TPG Biotech also invested in the round. The Seattle-based biotech added that venture capitalists Dr. Ketan Patel, Dr. Naveed Siddiqi, Tiba Aynechi, Niall O’Donnell and Dr. Heather Preston joined the baord of directors.

Dr. Bruce Montgomery was named CEO and the company’s founder, Mark Surber, was appointed chief scientific officer.

Genoa’s inhaled pirfendione, Aerodone, is slated to begin clinical development by the end of the year. An inhaled formulation of the drug would be a new offering for patients with IPF. The 1st and only 2 drugs approved by the FDA, oral pirfenidone and oral nintedanib, hit the market in 2014.

“In addition to advancing our early-stage pipeline, with this financing and our veteran development team, we have the funds and expertise to test Aerodone for the treatment of IPF through Phase II clinical trials,” Surber said in prepared remarks. “Despite the approval of 2 medicines, IPF remains a fatal disease with substantial unmet need for improved tolerability and effective medical treatments. By the inhaled approach, we are enthusiastic for the opportunity to meet these needs and improve patient lives.”

Oral pirfenidone is a low potency drug, according to Genoa, which means it requires a large dose to reach efficacious levels in the lungs. A large oral dose of pirfenidone comes with substantial side effects and therefore limits the deliverable dose. Genoa said its inhaled formulation could allow patients to take a larger dose while avoiding harmful side effects associated with oral delivery.

“Reformulating systemic drugs for targeted inhaled lung delivery has successfully improved the efficacy and decreased systemic adverse effects for corticosteroids and bronchodilators in both asthma and COPD, and antibiotics in cystic fibrosis,” Dr. Montgomery added. “We hope to accomplish the same benefits with pirfenidone.”

Filed Under: Featured, Funding Roundup, Respiratory Tagged With: genoapharmaceuticals

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS